Episode Details
Back to Episodes
Breakthrough Pill Extends Pancreatic Cancer Survival
Description
A breakthrough pill called daraxonrasib is giving advanced pancreatic cancer patients a fighting chance—doubling survival time and improving quality of life in a landmark study. Targeting a previously unreachable mutated protein, this drug outperformed chemotherapy, with patients living 13.2 months versus 6.7 months. Doctors were moved by the results, and regulators are fast-tracking approval. It could even open doors for earlier use and surgery eligibility—offering hope where there was once little.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/198be4f07606378c